SRAS COV2-RBD in complex with 2 potently neutralizing human antibodies (Fab)

References:

1. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, Liu Z, Whelan SPJ, Carnahan RH, Crowe JE, Bloom JD. “Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition.” bioRxiv [Preprint]. 2020 Sep 10:2020.09.10.292078. doi: 10.1101/2020.09.10.292078. (2020)

2. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez DR, Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai NM, Winkler ES, Fox JM, Shrihari S, Mueller BK, Meiler J, Chandrashekar A, Mercado NB, Steinhardt JJ, Ren K, Loo YM, Kallewaard NL, McCune BT, Keeler SP, Holtzman MJ, Barouch DH, Gralinski LE, Baric RS, Thackray LB, Diamond MS, Carnahan RH, Crowe JE Jr. “Potently neutralizing and protective human antibodies against SARS-CoV-2.” Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. (2020



Fig 1: SEC chromatogram of RBD Fab 2130/2196 complex. Peak 1, the complex . Peak 2, unbound Fabs .



Fig 2: Low mag image of the cryo grid.



Fig 3: micrographs of RBD Fab 2130/2196 complex in negative stain (left) and cryo (right).



Fig 4: 2D classes from the NS(top)/cryo sample collected on TF20/CCD.